8-K: Disc Medicine Presents Promising Initial PV Trial Results

Disc Medicine announced positive initial results from its RESTORE-PV Phase 2 trial of DISC-3405, demonstrating significant reductions in phlebotomy events and controlled hematocrit in polycythemia vera patients.

Summary

• Disc Medicine presented initial results from the RESTORE-PV Phase 2 clinical trial for DISC-3405 in patients with polycythemia vera (PV).
• The trial enrolled 40 adult participants, with data presented for Cohort A (n=20) and baseline/safety data for Cohorts A and B (n=20).
• Results showed DISC-3405 increased hepcidin, reduced serum iron, and maintained hematocrit below 45% through week 26 in Cohort A.
• Significantly, phlebotomy events decreased from a mean of 4.0 at baseline to 0.6 post-Day 1 over 26 weeks for 13 patients in Cohort A who completed the study.
• 61.5% of these participants remained phlebotomy-free post-baseline through 26 weeks.
• DISC-3405 was generally well-tolerated with mild and self-limited injection site reactions.
• Disc also presented data from the RALLY-MF trial of selcodebart and a literature review on anemia in myelofibrosis.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with initial clinical trial results showing promising efficacy and tolerability for DISC-3405 in treating polycythemia vera.

Positives

• DISC-3405 demonstrated a significant reduction in phlebotomy events, with 61.5% of participants in Cohort A remaining phlebotomy-free through 26 weeks.
• Mean hematocrit was stably maintained below 45% through week 26 in Cohort A, indicating effective disease control.
• The drug showed dose-proportional pharmacokinetics, elevated hepcidin, and reduced serum iron, aligning with its mechanism of action.
• Improved symptom burden was observed in Cohort A patients due to hematocrit control.
• DISC-3405 was generally well-tolerated with a low rate of mild and self-limited injection site reactions.
• The company has two programs (DISC-3405 and selcodebart) advancing toward potential pivotal development in myeloproliferative neoplasms.

Negatives

• Only efficacy data for Cohort A was presented; Cohort B had 18 of 20 participants dosed at the time of the data cut.
• The trial is open-label, which can introduce bias.
• Ferritin levels increased in Cohort A, which may warrant further monitoring in the context of iron homeostasis.

Risks

• The results are initial and from a Phase 2 trial; further studies are needed to confirm efficacy and safety.
• DISC-3405 is an investigational agent and not approved for use.
• New risks and uncertainties may emerge, and actual results could differ materially from forward-looking statements.
• The company's ability to successfully initiate and complete clinical trials and its capital adequacy are subject to risks.

Future Outlook

Disc plans to provide an update on the RESTORE-PV trial and initial data from the Phase 1b trial of DISC-3405 in sickle cell disease by the end of 2026. Additionally, the company expects to share feedback from an end-of-phase 2 meeting with the FDA regarding selcodebart and plans for pivotal development in anemia of myelofibrosis by the end of 2026.

Management Comments

• "This first look at data from the RESTORE-PV trial shows that the established pharmacodynamics of DISC-3405 are translating well on important clinical measures."
• "Iron restriction is proving to be a transformative treatment approach for a large population of patients with polycythemia vera, with the potential to address their crucial need for hematocrit control while managing symptom burden and reducing reliance on phlebotomy."
• "Our goal for DISC-3405 is to deliver an optimal product presentation combining durable disease control with straightforward, controllable, and convenient dosing using a novel antibody approach."
• "Between this update in PV and our earlier progress in MF this year, we have strengthened our commitment to hematologic oncology and now have two programs advancing toward potential pivotal development in myeloproliferative neoplasms."

Industry Context

StockSavvy.ai notes that the positive results for DISC-3405 in polycythemia vera align with the growing interest in targeting iron homeostasis for hematologic diseases. The success in reducing phlebotomy and controlling hematocrit addresses key unmet needs in PV management, a condition where current treatments often involve burdensome procedures or cytoreductive agents.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical trial results, potentially increasing the value of the company's stock.
• Patients with Polycythemia Vera: Potential for a new, more effective treatment option that reduces the need for phlebotomy and improves symptom burden.
• Healthcare Providers: May gain a new therapeutic tool for managing PV patients, potentially leading to better patient outcomes and reduced healthcare resource utilization associated with phlebotomy.

Next Steps

• Provide an update on RESTORE-PV by the end of 2026.
• Present initial data from the Phase 1b trial of DISC-3405 in sickle cell disease by the end of 2026.
• Share feedback from an end-of-phase 2 meeting with the FDA regarding selcodebart.
• Outline plans for pivotal development in anemia of myelofibrosis by the end of 2026.

Key Dates

Recommendation

The initial positive results are encouraging, but the data is from a Phase 2 trial and requires further validation in pivotal studies. While the drug shows promise in addressing key aspects of PV management, it is still investigational. Therefore, a 'hold' recommendation is appropriate pending further data and regulatory progress.

Keywords

Polycythemia Vera, DISC-3405, RESTORE-PV, Hematologic Diseases, Clinical Trial Results, Hepcidin, Phlebotomy, Myeloproliferative Neoplasms